Effect of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, on Systolic Blood Pressure in Patients with Type 2 Diabetes

Category Systematic review
ConferenceAmerican Heart Association's 2024 Scientific Sessions and the American Heart Association's 2024 Resuscitation Science Symposium
Year 2024
This article has no abstract
Epistemonikos ID: 590f5a96032540847e1dec63474437527d7625f8
First added on: Mar 26, 2025